Featured Research

from universities, journals, and other organizations

New treatment for psoriasis?

Date:
January 11, 2013
Source:
The Research Council of Norway
Summary:
Three per cent of the world’s population suffer from the skin condition known as psoriasis. A Norwegian research-based company is close to developing a treatment that could help millions. The research may also prove beneficial in the treatment of other illnesses.

Three per cent of the world's population suffer from the skin condition known as psoriasis. A Norwegian research-based company is close to developing a treatment that could help millions. The research may also prove beneficial in the treatment of other illnesses.

The psoriasis treatment consists of a compound which, when applied to the skin, is absorbed by skin cells much more naturally than most other ointments. It contains a synthesised molecule based on the fatty acid docosahexaenoic acid (DHA) which may prove effective in inhibiting chronic inflammation associated with psoriasis.

Clinical trials soon underway

Avexxin, a Trondheim-based company, is to begin clinical testing of the ointment in early 2013. If the results are positive, Avexxin may find itself on the cusp of an international breakthrough.

Successful tests of the psoriasis compound could also give an important boost to the pursuit of more comprehensive clinical trials to determine whether the technology can be applied to other chronic inflammatory conditions such as rheumatoid arthritis and nephritis, an inflammation in the kidneys.

Combining clinical phases 1 and 2A

Clinical trials often extend over a long period of time. The treatment must first be tested for toxicity on healthy volunteers. Subsequent trials must be carried out on real patients to ensure that the treatment has the desired effect. With an ointment such as this, which is to be applied externally, it is possible to combine trial phases 1 and 2A.

"This enables us to save a lot of time," explains Professor Berit Johansen of the Norwegian University of Science and Technology (NTNU). Dr Johansen has been studying the mechanisms behind inflammatory disease since the end of the 1980s. She launched the company, Avexxin, in 2005.

Potential for treating other conditions

Two Avexxin projects have received funding under the programme for User-driven Research-based Innovation (BIA) at the Research Council of Norway:

  • Development of mechanism based, novel anti-inflammatory compounds (2006-2009)
  • Expanding drug pipeline in Avexxin -- adopting new chemistry (2009-2012)

"We have been lucky in obtaining private funding that supports our main focus -- the development of a medicine for treating psoriasis," Dr Johansen explains.

"The financial support we have received from the Research Council has been critical to our research and has enabled us to develop several molecules to treat other inflammatory conditions with the same treatment target as psoriasis. These molecules could prove effective in treating rheumatoid arthritis and nephritis," Dr Johansen states.

"When we carried out tests in summer 2012 to see whether one of the new molecules might have any effect on arthritis in animals, the results were extremely encouraging."


Story Source:

The above story is based on materials provided by The Research Council of Norway. Note: Materials may be edited for content and length.


Cite This Page:

The Research Council of Norway. "New treatment for psoriasis?." ScienceDaily. ScienceDaily, 11 January 2013. <www.sciencedaily.com/releases/2013/01/130111092533.htm>.
The Research Council of Norway. (2013, January 11). New treatment for psoriasis?. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2013/01/130111092533.htm
The Research Council of Norway. "New treatment for psoriasis?." ScienceDaily. www.sciencedaily.com/releases/2013/01/130111092533.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins